Novartis (NYSE: NVS) shares beat the market last month, gaining 11% compared to a 3.6% increase in the S&P 500 , according to data provided by S&P Global Market Intelligence .
The boost still left shareholders in negative territory, as the stock has trailed the market so far in 2018.
^SPX data by YCharts .
July's rally came in response to the solid second-quarter earnings results that the biotech giant announced in the middle of the month. Sales grew 5% on a constant currency basis thanks to strong growth in franchises, including Cosentyx and Entresto. These top-line gains helped push profitability higher, as operating income grew 6%.
Image source: Getty Images.
Novartis recently confirmed management's 2018 sales and earnings forecasts, which call for revenue to grow in the low- to mid-single-digit range, with operating income slightly outpacing that result. There are three potential blockbuster treatments in the pipeline for the second half of the year, followed by four in 2019 -- including AveXis -- and six in fiscal 2020.
Novartis will need to continue spending on research and development to support that pipeline, but investors can generally expect to see modest earnings growth that's supplemented by aggressive stock repurchase spending.
10 stocks we like better than Novartis
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Novartis wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Demitrios Kalogeropoulos has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .